Skip to content

NASDAQ · large · thesis board

SNY Sanofi

BTK inhibitor (tolebrutinib)

View race

Thesis

Editorial summary — not a primary filing

Tolebrutinib BTK path in MS; large-cap balance sheet absorbs late-stage risk.

Next gate

2026-09-28ConfirmedPDUFA

PDUFA — tolebrutinib

46 days · FDA: FDA / company PDUFA disclosure

Survive-to-Event

ok

Cash covers the next gate with ~25 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~811d)100%
Days to gate (46d)6%
Show math

$8.0B cash ÷ $300M/mo burn ≈ 811 days. Source: curated SEC quarter figures.

Cash $8.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
RHHBYPh3okNVSPh3okPRTAPh2ok

Risks

  • Liver safety narrative
  • Anti-CD20 incumbents
  • Label scope
  • Timing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04458051as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01